# Evaluating Therapeutic Response to Novo-TTF

> **NCT02441322** · NA · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 30 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DEVICE:** Novo-TTF

## Key facts

- **NCT ID:** NCT02441322
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2023-06
- **Final completion:** 2023-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02441322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02441322, "Evaluating Therapeutic Response to Novo-TTF". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02441322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*